Capmatinib - Novartis Oncology

Drug Profile

Capmatinib - Novartis Oncology

Alternative Names: INC-280; INCB-028060; INCB-28060

Latest Information Update: 25 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Incyte Corporation
  • Developer Array BioPharma; Novartis Oncology
  • Class Antineoplastics; Benzamides; Heterocyclic bicyclo compounds; Imidazoles; Quinolines; Small molecules; Triazines
  • Mechanism of Action Proto oncogene protein c met inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Non-small cell lung cancer
  • Phase II Glioblastoma; Hepatocellular carcinoma; Malignant melanoma
  • Phase I/II Colorectal cancer; Head and neck cancer
  • Phase I Renal cell carcinoma; Solid tumours

Most Recent Events

  • 16 Jul 2018 Novartis withdraws a phase II trial for Non-small cell lung cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater) prior to enrolment (NCT03240393)
  • 16 May 2018 Novartis Pharmaceuticals completes a phase I trial for Solid tumours (Late-stage disease) in Denmark, United Kingdom, USA, Sweden, Netherlands, Spain, Germany, Austria (PO, Tablet) (NCT02925104)
  • 25 Apr 2018 Novartis terminates a phase-I/II trial in Glioblastoma (Combination therapy, Recurrent, Second-line therapy or greater) in USA, Germany, Netherlands, Spain, Switzerland (PO) (NCT01870726)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top